Sildenafil/Tadafil blend analysisTargeted HPLC analysis of sildenafil and tadalafil blends in pills, tablets, and capsules, confirming identity and determining the amount of both compounds.
Features

Sildenafil/Tadafil blend analysis

The Sildenafil/Tadalafil Blend Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil and tadalafil in combined oral dosage forms.

The analysis is suitable for pills, tablets, and capsules containing both compounds, with individual results reported in milligrams per tablet or capsule.

About Sildenafil and Tadalafil

Sildenafil and tadalafil are orally active phosphodiesterase type 5 (PDE5) inhibitors. Both compounds inhibit PDE5 and support the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.

Although they belong to the same pharmacological class, sildenafil and tadalafil differ in their pharmacokinetic profiles and duration of action. This analysis is specifically designed for products containing both compounds in a single formulation.

Key Features

  • Targeted identification and quantification of sildenafil and tadalafil
  • Suitable for combined pills, tablets, and capsules
  • Simultaneous analysis of both target compounds
  • Analysis by HPLC
  • Results reported individually for sildenafil and tadalafil
  • Results reported in mg per tablet or capsule
  • Minimum sample amount of three tablets or capsules
  • Average turnaround time of 7 business days

Analysis Parameters

  • Target compounds: Tadalafil and Sildenafil
  • Testing method: HPLC
  • Minimum amount of target compound for evaluation: 2 mg
  • Result format: mg per tablet or capsule
  • Minimum sample amount: Three tablets or capsules
  • Average turnaround time: 7 business days

Important Notice

  • This analysis is specifically intended for products containing sildenafil and tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.
  • The minimum amount of each target compound required for evaluation is 2 mg. Samples containing lower amounts may not be reliably evaluated within the standard scope of the analysis.

Optional Additional Analyses

The following optional laboratory services are available: